WS Management’s Adaptimmune Therapeutics ADAP Stock Holding History

WS Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-115,602	Closed	-$124K	–	68
2022 Q3	$124K	Hold	115,602	–	–	0.01%	70
2022 Q2	$197K	Hold	115,602	–	–	0.02%	74
2022 Q1	$238K	Hold	115,602	–	–	0.01%	66
2021 Q4	$434K	Hold	115,602	–	–	0.03%	59
2021 Q3	$598K	Hold	115,602	–	–	0.06%	67
2021 Q2	$492K	Hold	115,602	–	–	0.05%	70
2021 Q1	$614K	Sell	115,602 -5,941	-5%	-$34K	0.06%	61
2020 Q4	$655K	Hold	121,543	–	–	0.07%	52
2020 Q3	$970K	Hold	121,543	–	–	0.1%	54
2020 Q2	$1.22M	Sell	121,543 -20,831	-15%	-$131K	0.15%	46
2020 Q1	$387K	Sell	142,374 -7,133	-5%	-$23.7K	0.04%	63
2019 Q4	$179K	Hold	149,507	–	–	0.02%	56
2019 Q3	$226K	Sell	149,507 -16,440	-10%	-$38.4K	0.02%	63
2019 Q2	$667K	Sell	165,947 -19,590	-11%	-$79.9K	0.04%	64
2019 Q1	$798K	Sell	185,537 -24,922	-12%	-$116K	0.05%	65
2018 Q4	$1.21M	Sell	210,459 -86,324	-29%	-$637K	0.06%	73
2018 Q3	$4.02M	Hold	296,783	–	–	0.13%	68
2018 Q2	$3.52M	Buy	+296,783	New	+$3.7M	0.1%	68

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

WS Management's ADAP Position: Q4 2022 in Review

WS Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 115,602 shares — an estimated $124K sold.

WS Management first reported a position in ADAP in Q2 2018 and held it in 18 quarters. The position peaked at $4.02M in Q3 2018. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

WS Management reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
WS Management sold 115,602 Adaptimmune Therapeutics shares in Q4 2022, an estimated $124K.
WS Management first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 18 quarters.
WS Management's Adaptimmune Therapeutics position peaked at $4.02M in Q3 2018.
69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on WS Management's 13F filing for Q4 2022, filed 14 Feb 2023.